MARKET

IONS

IONS

Isis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

56.65
-0.41
-0.72%
After Hours: 56.65 0 0.00% 17:26 11/11 EST
OPEN
56.88
PREV CLOSE
57.06
HIGH
57.20
LOW
55.25
VOLUME
624.85K
TURNOVER
--
52 WEEK HIGH
86.58
52 WEEK LOW
48.27
MARKET CAP
7.97B
P/E (TTM)
19.76
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IONS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 16 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

IONS News

  • Edited Transcript of IONS earnings conference call or presentation 6-Nov-19 4:30pm GMT
  • Thomson Reuters StreetEvents.15h ago
  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.3d ago
  • Benzinga's Top Upgrades, Downgrades For November 7, 2019
  • Benzinga.4d ago
  • Piper Jaffray Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $70
  • Benzinga.4d ago

More

Industry

Biotechnology & Medical Research
-0.51%
Pharmaceuticals & Medical Research
-0.43%

Hot Stocks

Name
Price
%Change

About IONS

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
More

Webull offers Ionis Pharmaceuticals Inc (IONS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.